US2004161393A1PendingUtilityA1

Dual inhibitors of cholesteryl ester and wax ester synthesis for sebaceous gland disorders

48
Priority: Feb 2, 2000Filed: Feb 6, 2004Published: Aug 19, 2004
Est. expiryFeb 2, 2020(expired)· nominal 20-yr term from priority
Inventors:Reynold Homan
A61P 43/00A61P 17/00A61P 17/08A61P 17/10A61K 31/255
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a method of treating sebaceous gland disorders comprising administering to a patient in need of said treatment an effective amount of a compound named [(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-phenyl ester or a pharmaceutically acceptable salt thereof. Particularly, methods of treating sebaceous gland disorders are provided wherein said disorders are selected from seborrhea, acnes, perioral dermatitis, rosacea, and corticosteroid-induced acneiform lesions. The present invention provides methods of treating acnes such as, for example, chloracne, ciliaris acne, cystic acne, keratosa acne, vulgaris acne, senile acne, and medicinal acne.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method of treating sebaceous gland disorders comprising administering to a patient in need of said treatment an effective amount of a compound named [(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-phenyl ester or a pharmaceutically acceptable salt thereof.  
     
     
         2 . A method according to  claim 1  wherein said disorder is seborrhea.  
     
     
         3 . A method according to  claim 1  wherein said disorders are acnes.  
     
     
         4 . A method according to  claim 1  wherein said disorder is chloracne.  
     
     
         5 . A method according to  claim 1  wherein said disorder is ciliaris acne.  
     
     
         6 . A method according to  claim 1  wherein said disorder is cystic acne.  
     
     
         7 . A method according to  claim 1  wherein said disorder is keratosa acne.  
     
     
         8 . A method according to  claim 1  wherein said disorder is vulgaris acne.  
     
     
         9 . A method according to  claim 1  wherein said disorder is senile acne.  
     
     
         10 . A method according to  claim 1  wherein said disorder is medicinal acne.  
     
     
         11 . A pharmaceutical composition comprising an acne-inhibiting amount of a compound named [(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-phenyl ester and a pharmaceutically acceptable carrier.  
     
     
         12 . A method of treating acnes comprising administering to a patient in need of said treatment an acne-inhibiting amount of a compound named [(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-phenyl ester or a pharmaceutically acceptable salt thereof.  
     
     
         13 . The use of a compound named [(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-phenyl ester for the manufacture of a medicament for the treatment of acnes.  
     
     
         14 . A method according to  claim 1  wherein said disorder is perioral dermatitis.  
     
     
         15 . A method according to  claim 1  wherein said disorder is rosacea.  
     
     
         16 . A method according to  claim 1  wherein said disorder is corticosteroid-induced acneiform lesions.  
     
     
         17 . A pharmaceutical composition comprising a sebaceous gland secretion-inhibiting amount of a compound named [(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-phenyl ester and a pharmaceutically acceptable carrier.  
     
     
         18 . The use of a compound named [(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-phenyl ester for the manufacture of a medicament for the treatment of diseases caused by sebaceous gland disorders.  
     
     
         19 . A method of inhibiting AFAT comprising administering to a patient in need of said treatment an AFAT inhibiting amount of a compound named [(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-phenyl ester or a pharmaceutically acceptable salt thereof.  
     
     
         20 . A method of inhibiting ACAT and AFAT comprising administering to a patient in need of said treatment an ACAT and AFAT inhibiting amount of a compound named [(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-phenyl ester.  
     
     
         21 . A method of inhibiting sebum production in a human in need of said treatment comprising administering to said human a sebum production-inhibiting amount of [(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-phenyl ester or a pharmaceutically acceptable salt thereof.  
     
     
         22 . A method according to  claim 21 , which is used to treat oily skin.

Join the waitlist — get patent alerts

Track US2004161393A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.